Merck achieves positive results in Phase 3 trials of insomnia drug
Merck & Co. said it achieved positive results in Phase 3 trials of its experimental insomnia treatment, a key drug in the pharmaceutical giant's pipeline.
Merck & Co. presented positive data from a mid-stage study of one of its pipeline candidates at SLEEP 2010, the annual meeting of the Associated Professional Sleep Societies.